Global Cell Harvesting System Market Size study, by Type (Manual, Automated), by Application (Umbilical Cord, Bone Marrow, Peripheral Blood), by End-use, and Regional Forecasts 2022-2032

The Global Cell Harvesting System Market is valued approximately at USD 5.23 billion in 2023 and is anticipated to grow with a promising CAGR of more than 14.40% over the forecast period 2024-2032. Cell harvesting systems represent an indispensable cornerstone in regenerative medicine, cellular therapy, and advanced biomedical research. These cutting-edge systems allow for the efficient extraction and preservation of vital cells from various biological sources such as bone marrow, umbilical cord blood, and peripheral blood-key elements in curative therapies for cancer, immune disorders, and chronic illnesses. Fueled by rapid technological advancements and growing reliance on personalized medicine, the global market for cell harvesting systems is advancing toward fully automated, highly scalable solutions capable of handling vast sample volumes with minimal contamination risks.

The momentum in this market is being driven by a surge in stem cell research, rising investment in cell-based therapies, and increasing prevalence of conditions such as leukemia, multiple myeloma, and autoimmune diseases. Biopharma innovators and healthcare institutions alike are intensifying their focus on integrating automated harvesting systems that not only ensure higher cell viability and recovery rates but also streamline lab operations. Further bolstering the industry's growth is a rise in public and private R&D spending and government-backed initiatives supporting biotechnological innovation. However, the adoption of these systems continues to face headwinds from high equipment costs, complex workflows, and the need for skilled personnel to operate and maintain these systems-particularly in low-resource settings.

Over the last few years, the evolution from manual to automated harvesting platforms has emerged as a game-changer. Automated systems offer real-time monitoring, user-friendly interfaces, and reproducible results-all essential for scaling clinical trials and therapeutic production. Their integration with AI-driven diagnostics and robotic handling systems has enabled precise sample preparation and minimized human error. As pharmaceutical and biotech firms gear up to meet the rising global demand for cell-based products, these sophisticated systems are fast becoming a strategic investment. Additionally, novel harvesting techniques using closed-loop environments and sterile processing chambers are further reducing contamination risks and improving patient safety outcomes.

Another noteworthy trend reshaping the market is the increasing utility of cell harvesting systems in umbilical cord blood banking and peripheral blood stem cell collection, particularly for pediatric and oncology applications. The bone marrow segment, while still dominant, is gradually being complemented by these less invasive alternatives, particularly as research into induced pluripotent stem cells (iPSCs) and allogeneic therapies gains ground. Collaborations between medical device manufacturers and research institutions are also enhancing product innovation-ushering in an era of smart harvesting technologies tailored for high-throughput and multi-sample environments.

Regionally, North America commands the largest market share, underpinned by a robust clinical research ecosystem, progressive reimbursement frameworks, and the presence of major life science firms. The United States, in particular, leads with its advanced infrastructure, continuous innovation, and FDA-backed regenerative medicine initiatives. Europe follows closely with strong research support from countries such as Germany, the UK, and Switzerland. Meanwhile, Asia Pacific is emerging as the fastest-growing region due to rising healthcare expenditure, expanding biotech clusters in China and India, and growing participation in global cell therapy trials. Latin America and the Middle East & Africa, though relatively nascent, are witnessing gradual adoption spurred by improved healthcare access and strategic collaborations in medical innovation.

Major market player included in this report are:

• Terumo BCT, Inc.
• STEMCELL Technologies Inc.
• PerkinElmer, Inc.
• GE Healthcare
• Thermo Fisher Scientific Inc.
• Sartorius AG
• Miltenyi Biotec
• Merck KGaA
• Danaher Corporation
• Avita Medical
• Argos Technologies, Inc.
• Asahi Kasei Corporation
• BD (Becton, Dickinson and Company)
• Corning Incorporated
• Bio-Rad Laboratories, Inc.

The detailed segments and sub-segment of the market are explained below:

By Type

• Manual
• Automated

By Application

• Umbilical Cord
• Bone Marrow
• Peripheral Blood

By End-use

• Hospitals and Clinics
• Research and Academic Institutes
• Biotechnology and Pharmaceutical Companies
• Blood Banks

By Region:

• North America
• U.S.
• Canada
• Europe
• UK
• Germany
• France
• Spain
• Italy
• Rest of Europe
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• Rest of Asia Pacific
• Latin America
• Brazil
• Mexico
• Rest of Latin America
• Middle East & Africa
• Saudi Arabia
• South Africa
• Rest of Middle East & Africa

Years considered for the study are as follows:

• Historical year - 2022
• Base year - 2023
• Forecast period - 2024 to 2032

Key Takeaways:

• Market Estimates & Forecast for 10 years from 2022 to 2032.
• Annualized revenues and regional level analysis for each market segment.
• Detailed analysis of geographical landscape with Country level analysis of major regions.
• Competitive landscape with information on major players in the market.
• Analysis of key business strategies and recommendations on future market approach.
• Analysis of competitive structure of the market.
• Demand side and supply side analysis of the market.